There were 18,009 women diagnosed with ER+/HER2− BC, 3,325 with ER+/HER2+ BC, 7,958 with ER−/HER2+ BC, and 22,625 with TNBC (Table 1). This evidence concerns the gene ERBB2 and breast cancer.